769944-85-6

Upstream product

• 99-73-0 para-bromophenacyl bromide 
• 96855-38-8 (R)?2?bromo?1?(4′?bromophenyl)ethanol 
• 62566-68-1 (R)-2-(4-bromophenyl)oxirane 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 769944-65-2 (S)-1,4-di(t-butoxycarbonyl)-2-(4'-methoxybiphen-4-yl)piperazine 
• 769944-57-2 (S)-1,4-di-(t-butoxycarbonyl)-2-(4-((R)-3-hydroxypyrrolidino)phenyl)piperazine 
• 881919-93-3 (2S)-2-(4-piperidin-1-yl-phenyl)-piperazine-1,4-dicarboxylic acid di-tert-butyl ester 
• 769944-63-0 (S)-1,4-di(t-butoxycarbonyl)-2-(4-(N,N-dimethylamino)phenyl)piperazine 

Relevant academic research and scientific papers

Asymmetric synthesis of 2-arylpiperazines

An asymmetric synthesis of 2-arylpiperazines starting from phenacyl bromides, a variety of which are easily available, has been established. The synthesis features a CBS reduction of phenacyl bromide to provide optically enriched compounds, an SN2 reaction of 1,2,3-oxathiazolidine 2-oxides with an azide anion with invert of configuration, and construction of the piperazine ring via reduction of piperazine-2,3-diones.

PYRIMIDONE COMPOUND

A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof:wherein R1 represents a C1-C12 alkyl; R2 represents a hydrogen atom or the like; R3 represents a halogen or the like; q represents an integer of 1 to 7; R4 represents a halogen or the like; p represents 0 or an integer of 1 to 5; R5 represents a C6-C10 aryl, a heterocycle or the like; and X represents oxygen, NH, or the like, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).